Bristol-Myers Squibb Company
BMY
$43.41
-$0.75-1.70%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.57% | 4.62% | 7.32% | 5.56% | 2.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.57% | 4.62% | 7.32% | 5.56% | 2.93% |
| Cost of Revenue | 12.31% | 10.45% | 13.61% | 10.77% | 9.60% |
| Gross Profit | -0.48% | 2.78% | 5.40% | 4.01% | 1.00% |
| SG&A Expenses | -8.73% | -5.71% | 1.86% | 2.02% | 1.37% |
| Depreciation & Amortization | -38.12% | -19.71% | -1.93% | 3.79% | 0.36% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.73% | -1.86% | 5.69% | 5.32% | 3.24% |
| Operating Income | 41.66% | 33.53% | 14.16% | 6.60% | 1.63% |
| Income Before Tax | 202.73% | 204.48% | -199.28% | -179.77% | -173.81% |
| Income Tax Expenses | 1,302.75% | 132.18% | 38.50% | 13.98% | -84.86% |
| Earnings from Continuing Operations | 177.59% | 188.62% | -211.11% | -187.28% | -181.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -23.08% | -38.46% | 0.00% | 38.89% | 7.14% |
| Net Income | 177.19% | 188.14% | -211.50% | -187.60% | -182.14% |
| EBIT | 41.66% | 33.53% | 14.16% | 6.60% | 1.63% |
| EBITDA | 1.08% | 5.53% | 5.53% | 5.23% | 1.08% |
| EPS Basic | 176.42% | 186.41% | -214.24% | -190.62% | -186.04% |
| Normalized Basic EPS | 27.04% | 16.11% | -0.60% | 3.11% | 3.43% |
| EPS Diluted | 175.75% | 185.77% | -214.81% | -191.24% | -186.76% |
| Normalized Diluted EPS | 26.92% | 16.08% | -0.31% | 3.54% | 3.91% |
| Average Basic Shares Outstanding | -0.14% | -1.04% | -2.04% | -3.02% | -3.55% |
| Average Diluted Shares Outstanding | -0.04% | -1.03% | -2.31% | -3.42% | -3.98% |
| Dividend Per Share | 3.80% | 4.27% | 4.76% | 5.26% | 5.33% |
| Payout Ratio | 2.34% | 2.17% | -1.92% | -2.16% | -2.24% |